Fort Myers, Fla.-based NeoGenomics Laboratories agreed to pay $9.8 million to resolve allegations that it violated the Anti-Kickback Statute and Stark law through two separate arrangements involving referring physicians and independent consultants, according to a settlement agreement signed July 20, 2026.
The covered conduct ran from February 2014 through December 2022. Of the total settlement amount, $6.5 million is restitution.
The government alleged NeoGenomics violated the law through two distinct arrangements. First, through its Laboratory Clinical Initiative program, NeoGenomics provided laboratory consulting services to 28 healthcare providers to help them develop in-house flow cytometry and FISH diagnostic testing capabilities at below fair market value, allegedly to induce referrals of clinical laboratory tests to NeoGenomics.
Second, NeoGenomics paid independent consultants to identify potential referring providers and recommend its laboratory services, with those payments varying based on the volume or value of referrals, which is a structure the AKS prohibits.
NeoGenomics voluntarily self-disclosed the potential violations to the HHS OIG’s Provider Self-Disclosure Protocol in November 2021, conducted an internal investigation, terminated responsible employees and ended the consulting arrangements at issue. The company received formal credit under DOJ guidelines for that cooperation. The settlement is not an admission of liability by NeoGenomics.
In exchange for the payment, the government released NeoGenomics from civil and administrative monetary claims related to the covered conduct. The agreement was signed by NeoGenomics CEO Tony Zook.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.